logo-loader
Advanced Oncotherapy PLC

Result of AGM

/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ca{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ca{}p.cy{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold}span.cw{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; text-align: center}p.da{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: center}span.ct{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.db{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.cr{color:black}p.dc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center} span.cq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.dd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Arial","sans-serif";color:black;text-align:justify}span.cp{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.de{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.df{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.dg{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}table.di{width:481.5pt;border-collapse:collapse}td.cj{width:207.75pt;padding:0cm 5.4pt 0cm 5.4pt} td.cg{width:252.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.dj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: right}span.ci{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}p.dk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}span.dl{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.dm{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.ce{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext}span.dn{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.do{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify} span.dp{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}p.dr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}p.ds{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white}p.dt{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-left:0cm;text-align:justify} /**/
RNS Number : 7733V
Advanced Oncotherapy PLC
25 July 2018
 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Result of AGM

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

For further information, please contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / Ed Thomas

Tel: +44 20 7601 6100



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus

Mob: +44 7876 741 001 /Mob: +44 7980 541 893

 

 

About Advanced Oncotherapy plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSEEFLIFASEDW

Quick facts: Advanced Oncotherapy PLC

Price: £0.39

Market: LSE
Market Cap: £89.79 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

RNS

Second Price Monitoring Extn

2 weeks, 3 days ago

Price Monitoring Extension

2 weeks, 3 days ago

Result of AGM

4 weeks, 1 day ago

Final Results

on 28/6/19